{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T22:23:15Z","timestamp":1769552595760,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s12328-023-01832-8","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T12:01:51Z","timestamp":1690027311000},"page":"720-725","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness of tacrolimus in a case of immune checkpoint inhibitor-induced hepatotoxicity that was refractory to steroids and mycophenolate mofetil"],"prefix":"10.1007","volume":"16","author":[{"given":"Kosuke","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1171-7835","authenticated-orcid":false,"given":"Jun","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akitoshi","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mio","family":"Tsuruoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masazumi","family":"Onuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Sawahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keishi","family":"Ouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Masamune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,22]]},"reference":[{"key":"1832_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"1832_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and Anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86.","journal-title":"Front Oncol"},{"key":"1832_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2147\/CMAR.S52543","volume":"6","author":"B Ledezma","year":"2013","unstructured":"Ledezma B, Heng A. Real-world impact of education: treating patients with ipilimumab in a community practice setting. Cancer Manag Res. 2013;6:5\u201314.","journal-title":"Cancer Manag Res"},{"key":"1832_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","volume":"20","author":"SL Maude","year":"2014","unstructured":"Maude SL, Barrett D, Teachey DT, et al. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20:119\u201322.","journal-title":"Cancer J"},{"key":"1832_CR5","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3389\/fimmu.2014.00206","volume":"5","author":"YC Kong","year":"2014","unstructured":"Kong YC, Flynn JC. Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors Anti-CTLA-4 and Anti-PD-1. Front Immunol. 2014;5:206.","journal-title":"Front Immunol"},{"key":"1832_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nrclinonc.2013.245","volume":"11","author":"TC Gangadhar","year":"2014","unstructured":"Gangadhar TC, Vonderheide RH. Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol. 2014;11:91\u20139.","journal-title":"Nat Rev Clin Oncol"},{"key":"1832_CR7","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073\u2013126.","journal-title":"J Clin Oncol"},{"key":"1832_CR8","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1217\u201338.","journal-title":"Ann Oncol"},{"key":"1832_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","volume":"17","author":"JA Thompson","year":"2019","unstructured":"Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2019. J Natl Compr Canc Netw. 2019;17:255\u201389.","journal-title":"J Natl Compr Canc Netw."},{"key":"1832_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/hep.31227","volume":"72","author":"TB Peeraphatdit","year":"2020","unstructured":"Peeraphatdit TB, Wang J, Odenwald MA, et al. Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation. Hepatology. 2020;72:315\u201329.","journal-title":"Hepatology"},{"key":"1832_CR11","doi-asserted-by":"publisher","first-page":"e0217276","DOI":"10.1371\/journal.pone.0217276","volume":"14","author":"T Affolter","year":"2019","unstructured":"Affolter T, Llewellyn HP, Bartlett DW, et al. Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice. PLoS ONE. 2019;14:e0217276.","journal-title":"PLoS ONE"},{"key":"1832_CR12","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10620-012-2140-5","volume":"57","author":"DE Kleiner","year":"2012","unstructured":"Kleiner DE, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci. 2012;57:2233\u201340.","journal-title":"Dig Dis Sci"},{"key":"1832_CR13","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","volume":"31","author":"Y Zen","year":"2018","unstructured":"Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018;31:965\u201373.","journal-title":"Mod Pathol"},{"key":"1832_CR14","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1097\/COC.0000000000000374","volume":"41","author":"BM Huffman","year":"2018","unstructured":"Huffman BM, Kottschade LA, Kamath PS, et al. Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management. Am J Clin Oncol. 2018;41:760\u20135.","journal-title":"Am J Clin Oncol"},{"key":"1832_CR15","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/flgastro-2018-101146","volume":"10","author":"V Cheung","year":"2019","unstructured":"Cheung V, Gupta T, Payne M, et al. Immunotherapy-related hepatitis: real-world experience from a tertiary centre. Frontline Gastroenterol. 2019;10:364\u201371.","journal-title":"Frontline Gastroenterol"},{"key":"1832_CR16","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00262-017-2107-7","volume":"67","author":"HM McGuire","year":"2018","unstructured":"McGuire HM, Shklovskaya E, Edwards J, et al. Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. Cancer Immunol Immunother. 2018;67:563\u201373.","journal-title":"Cancer Immunol Immunother"},{"key":"1832_CR17","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/1078155217745144","volume":"25","author":"CR Stroud","year":"2019","unstructured":"Stroud CR, Hegde A, Cherry C, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 2019;25:551\u20137.","journal-title":"J Oncol Pharm Pract"},{"key":"1832_CR18","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jhep.2018.10.020","volume":"70","author":"M Riveiro-Barciela","year":"2019","unstructured":"Riveiro-Barciela M, Mu\u00f1oz-Couselo E, Fernandez-Sojo J, et al. Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: new settings call for new treatment strategies? J Hepatol. 2019;70:564\u20136.","journal-title":"J Hepatol"},{"key":"1832_CR19","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1007\/s12072-021-10238-y","volume":"15","author":"T Ito","year":"2021","unstructured":"Ito T, Ishigami M, Yamamoto T, et al. Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies. Hepatol Int. 2021;15:1278\u201387.","journal-title":"Hepatol Int"},{"key":"1832_CR20","doi-asserted-by":"publisher","first-page":"e000268","DOI":"10.1136\/esmoopen-2017-000268","volume":"2","author":"GJ Doherty","year":"2017","unstructured":"Doherty GJ, Duckworth AM, Davies SE, et al. Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. ESMO Open. 2017;2:e000268.","journal-title":"ESMO Open"},{"issue":"Suppl s1","key":"1832_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/ajt.15674","volume":"20","author":"A Kwong","year":"2020","unstructured":"Kwong A, Kim WR, Lake JR, et al. OPTN\/SRTR 2018 annual data report: liver. Am J Transplant. 2020;20(Suppl s1):193\u2013299.","journal-title":"Am J Transplant"},{"key":"1832_CR22","doi-asserted-by":"publisher","first-page":"100170","DOI":"10.1016\/j.jhepr.2020.100170","volume":"2","author":"E De Martin","year":"2020","unstructured":"De Martin E, Michot JM, Rosmorduc O, et al. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Rep. 2020;2:100170.","journal-title":"JHEP Rep"},{"key":"1832_CR23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1365-2141.2009.07714.x","volume":"146","author":"D DiMaggio","year":"2009","unstructured":"DiMaggio D, Anderson A, Bussel JB. Cytomegalovirus can make immune thrombocytopenic purpura refractory. Br J Haematol. 2009;146:104\u201312.","journal-title":"Br J Haematol"},{"key":"1832_CR24","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/s41467-021-21572-y","volume":"12","author":"JA Hutchinson","year":"2021","unstructured":"Hutchinson JA, Kronenberg K, Riquelme P, et al. Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis. Nat Commun. 2021;12:1439.","journal-title":"Nat Commun"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-023-01832-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-023-01832-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-023-01832-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T15:24:56Z","timestamp":1695914696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-023-01832-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,22]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1832"],"URL":"https:\/\/doi.org\/10.1007\/s12328-023-01832-8","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,22]]},"assertion":[{"value":"22 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The other authors state that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"Written consent was obtained from the patient to publish the clinical and virological findings.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}